Alnylam Pharmaceuticals Inc. (ALNY) announced after the close Wednesday that it has decided to discontinue development of revusiran. The decision was made after the Data Monitoring Committee of the company's Phase 3 study of the drug recommended that dosing be suspended. The study data revealed an imbalance of mortality in the revusiran arm as compared to placebo.
from RTT - Before the Bell http://ift.tt/2e8uRtO
via IFTTT
No comments:
Post a Comment